文献速递甲状腺疾病

激光消融对比射频消融治疗良性非功能性甲状腺结节:随机、平行、开放标签试验(LARA试验)的六个月结果

Laser Ablation Versus Radiofrequency Ablation for Benign Non-Functioning Thyroid Nodules: Six-Month Results of a Randomized, Parallel, Open-Label, Trial (LARA Trial).
PubMed 文献 · Thyroid · 2020-03-17

这项为期六个月、随机、开放标签、平行试验比较了激光消融(LA)与射频消融(RFA)治疗良性非功能性甲状腺结节(BNTN)的疗效与安全性。60例患者随机1:1接受RFA或LA,六个月时RFA组结节体积缩小64.3%(95%CI 57.5-71.2),LA组缩小53.2%(95%CI 47.2-95.2;p=0.02),成功率两组无显著差异(RFA 86.7% vs LA 66.7%,p=0.13)。

要点

  • RFA组六个月结节体积缩小64.3%,LA组缩小53.2%,差异有统计学意义。
  • 成功率RFA组86.7% vs LA组66.7%,差异无统计学意义。
  • 两组不良反应率分别为RFA 37%(n=11)和LA 43%(n=13),均无需住院。

核心结论

  • 尽管RFA与LA两组成功率相似,RFA在六个月时实现了显著更大的结节体积缩小。

研究设计与样本

  • 为期六个月、单次使用、随机、开放标签、平行试验,于2016年1月至2018年11月纳入60例患者,随机1:1接受LA或RFA。
  • 纳入孤立性BNTN或主导结节伴压迫症状/美容问题,或无自觉症状但一年内体积增加>20%的患者;结节均行粗针活检诊断。

主要发现

  • 六个月结节体积缩小:RFA组64.3%(95%CI 57.5-71.2) vs LA组53.2%(95%CI 47.2-95.2;p=0.02)。
  • 经年龄、基线体积和细胞成分比例校正的线性回归模型证实该效应(LA vs RFA百分比变化Δ=-12.8,p=0.02)。
  • 六个月成功率(结节缩小>50%的比例):RFA组86.7% vs LA组66.7%(p=0.13),无显著差异。
  • 两组促甲状腺激素水平无显著差异。
  • 压迫症状改善:RFA组2.13 vs 3.9(p<0.001);LA组2.4 vs 3.87(p<0.001);美容评分:RFA组1.65 vs 2.2(p<0.001);LA组1.85 vs 2.2(p<0.001);组间无显著差异。

关键数值与推荐

  • 主要终点之一为结节体积缩小百分比(以基线体积的百分比表示)。
  • 主要终点之二为结节缩小>50%的比例(成功率)。
  • 共纳入60例患者,随机1:1分配至RFA或LA。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: No direct prospective studies comparing laser ablation (LA) and radiofrequency ablation (RFA) for debulking benign non-functioning thyroid nodules (BNTNs) exist. We aimed at comparing the efficacy and safety of both techniques in patients with solid or predominantly solid BNTN. Methods: This six-month, single-use, randomized, open-label, parallel trial compared the following primary endpoints between the RFA and LA groups six months after treatment: (i) nodule volume reduction expressed as a percentage of nodule volume at baseline; (ii) proportion of nodules with more than 50% reduction (successful rate). We enrolled subjects with a solitary BNTN or dominant nodule characterized by pressure symptoms/cosmetic problems or patients without symptoms who experienced a volume increase >20% in one year. Nodules underwent core needle biopsy for diagnosis. Patients were randomly assigned (1:1) to receive LA or RFA. Safety was assessed in all randomly assigned participants. Results: Sixty patients were randomly assigned to receive either RFA or LA (1:1) between January 2016 and November 2018. Both groups were similar in basal nodule volume, thyroid function, histology, symptoms/cosmetic score, and procedure time. At six months, the nodule volume reduction was 64.3% (95% confidence interval, CI 57.5-71.2) in the RFA group and 53.2% ([CI 47.2-95.2]; p = 0.02) in the LA group. This effect was also confirmed in the linear regression model adjusted for age, baseline volume, and proportion of cellular component (LA vs. RFA percent change Delta = -12.8, p = 0.02). No significant difference was observed in success rate six months after treatment (RFA vs. LA: 86.7% vs. 66.7%, p = 0.13) or in thyrotropin level between the groups. Although improved, no significant difference was observed between RFA and LA for compressive symptoms (RFA: 2.13 vs. 3.9, p < 0 · 001; LA: 2.4 vs. 3.87, p < 0.001) and cosmetic score (RFA: 1.65 vs. 2.2, p < 0.001; LA: 1.85 vs. 2.2, p < 0.001). The adverse event rates (local pain, dysphonia, thyrotoxicosis, fever, hematoma) were 37% (n = 11) and 43% (n = 13) for RFA and LA, respectively, with no requirement for hospitalization. Conclusion: Although the success rate was similar in the RFA and LA groups, RFA achieved a significantly larger nodule volume reduction at six months.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Cesareo R, Pacella CM, Pasqualini V, et al. Laser Ablation Versus Radiofrequency Ablation for Benign Non-Functioning Thyroid Nodules: Six-Month Results of a Randomized, Parallel, Open-Label, Trial (LARA Trial). Thyroid. 2020. PMID: 32056501. doi:10.1089/thy.2019.0660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。